Skip to main content
. 2018 Mar 14;35(5):841–849. doi: 10.1007/s10815-018-1155-z

Table 1.

Baseline demographic characteristics of the untreated and IVM treated groups (n = 206)

Untreated group IVM treated group+
Cycle 1 Cycle 2 Cycle 1 Cycle 2
No IVM (n = 163) No IVM (n = 163) No IVM (n = 43) With IVM (n = 43)
Mean age (years)* 36.8 ± 4.3 37.3 ± 4.3 36.4 ± 4.4 36.9 ± 4.4
Mean BMI (kg/m2)** 25.6 ± 6.2 25.4 ± 6.1 25.9 ± 5.8 26.0 ± 5.8
 < 18.5 7 (4.4) 7 (4.3) 1 (2.3) 1 (2.4)
 18.5–24.9 89 (56.0) 94 (57.7) 22 (51.2) 21 (50.0)
 25.0–29.9 32 (20.1) 31 (19.0) 10 (23.3) 10 (23.8)
 30.0–39.9 24 (15.1) 24 (14.7) 8 (18.6) 8 (19.1)
 ≥ 40 7 (4.4) 7 (4.3) 2 (4.7) 2 (4.8)
Race/ethnicity**
 Caucasian 112 (68.7) 113 (69.3) 21 (48.8) 22 (51.2)
 Black or African-American 10 (6.1) 10 (6.1) 4 (9.3) 4 (9.3)
 Asian 10 (6.1) 10 (6.1) 7 (16.3) 8 (18.6)
 Hispanic 8 (4.9) 8 (4.9) 1 (2.3) 1 (2.3)
 Other 3 (1.8) 3 (1.8) 1 (2.3) 1 (2.3)
 Unknown 20 (12.2) 19 (11.7) 9 (21.0) 8 (18.6)
Diagnosis **++
 Tubal factor 19 (11.7) 20 (12.3) 1 (2.3) 1 (2.3)
 Uterine factor 7 (4.3) 7 (4.3) 1 (2.3) 1 (2.3)
 Endometriosis 11 (6.8) 11 (6.8) 1 (2.3) 1 (2.3)
 Ovulatory 17 (10.4) 17 (10.4) 3 (6.7) 2 (4.7)
 DOR 47 (28.8) 49 (30.1) 8 (18.6) 9 (20.9)
 Unexplained 40 (24.5) 40 (24.5) 15 (34.9) 16 (37.2)
 Male 51 (31.3) 50 (30.7) 16 (37.2) 16 (37.2)
 Other 27 (16.6) 28 (17.2) 5 (11.6) 5 (11.6)
 Gravid 73 (44.8) 85 (52.2) 25 (58.1) 24 (55.8)
 Parous 34 (20.9) 34 (20.9) 9 (20.9) 9 (20.9)
D3 FSH (mIU/mL)* 9.0 ± 5.5 9.2 ± 6.0 8.2 ± 4.2 7.8 ± 3.6
D3 estradiol (pg/mL)* 42.1 ± 22.8 40.7 ± 23.1 34.2 ± 23.2 34.4 ± 23.0
AMH (ng/mL)* 4.3 ± 7.7 4.4 ± 7.7 2.7 ± 2.1 2.6 ± 2.1
Cycle number* 1.2 ± 0.5 2.2 ± 0.5 2.0 ± 1.1 3.0 ± 1.1

+Defined by women who undergo IVM in cycle 2

*Values are mean ± SD

**Vales are number (% total)

++Some women possess multiple diagnoses and thus, these values do not add to 100%